Idiopathic pulmonary fibrosis: Molecular mechanisms and possible therapeutic strategies

Archivum Immunologiae et Therapiae Experimentalis

Volumn 48, Issue 6, 2000, Pages 539-545

  Van Den Blink, Bernt ^a   Jansen, Henk M ^a   Peppelenbosch, Maikel P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Apoptosis; Bleomycin; Fas; Fibrosis; Inflammation

Indexed keywords

BLEOMYCIN; CAPTOPRIL; COLLAGEN; FAS ANTIGEN; GAMMA INTERFERON; MITOGEN ACTIVATED PROTEIN KINASE; PREDNISOLONE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; IDIOPATHIC DISEASE; INCIDENCE; INFLAMMATION; LUNG FIBROSIS; NONHUMAN; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; CHEMOKINES; CYTOKINES; FIBRINOLYSIS; HERPESVIRUS 4, HUMAN; HUMANS; INFLAMMATION; MICE; PULMONARY FIBROSIS; T-LYMPHOCYTES;

EID: 0034488558     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. AGUSTI C., XAUBET A., BALLESTER E., ALARCON A. and PICADO C. (1993): Aerosolised ribavirin in patients with advanced cryptogenic fibrosing alveolitis: a pilot study. Thorax, 48, 68-69.
2. AOSHIBA K., YASUI S., HAYASHI M., TAMAOKI J. and NAGAI A. (1999): Role of p38-mitogen-activated protein kinase in spontaneous apoptosis of human neutrophils. J. Immunol., 162, 1692-1700.
3. ASHITANI J., MUKAE H., TANIGUCHI H., IHI T., KADOTA J., KOHNO S. and MATSUKURA S. (1999): Granulocyte-colony stimulating factor levels in bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis. Thorax, 54, 1015-1020.
4. BAUMGARTNER K. B., SAMET J. M., STIDLEY C. A., COLBY T. V. and WALDRON J. A. (1997): Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med., 155, 242-248.
5. BITTERMAN P. B., RENNARD S. I., KEOGH B. A., WEWERS M. D., ADELBERG S. and CRYSTAL R. G. (1986): Familial idiopathic pulmonary fibrosis. Evidence of lung inflammation in unaffected family members. N. Engl. J. Med., 314, 1343-1347.
6. BROEKELMANN T. J., LIMPER A. H., COLBY T. V. and MCDONALD J. A. (1991): Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc. Natl. Acad. Sci. USA, 88, 6642-6646.
7. CAMBREY A. D., HARRISON N. K., DAWES K. E., SOUTHCOTT A. M., BLACK C. M., DU BOIS R. M., LAURENT G. J. and MCANULTY R. J. (1994): Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am. J. Respir. Cell Mol. Biol., 11, 439-445.
8. CHAPMAN H. A. (1999): A Fas pathway to pulmonary fibrosis. J. Clin. Invest., 104, 1-2.
9. CHAPMAN H. A., ALLEN C. L. and STONE O. L. (1986): Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease. Am. Rev. Respir. Dis., 133, 437-443.
10. CHEN J. J., SUN Y. and NABEL G. J. (1998): Regulation of the proinflammatory effects of Fas ligand (CD95L). Science, 282, 1714-1717.
11. COKER R. K. and LAURENT G. J. (1998): Pulmonary fibrosis: cytokines in the balance. Eur. Respir. J., 11, 1218-1221.
12. COKER R. K., LAURENT G. J., SHAHZEIDI S., LYMPANY P. A., DU BOIS R. M., JEFFERY P. K. and MCANULTY R. J. (1997): Transforming growth factors-beta 1, -beta 2, and -beta 3 stimulate fibroblast procollagen production in vitro but are differentially expressed during bleomycin-induced lung fibrosis. Am. J. Pathol., 150, 981-991.
13. COULTAS D. B., ZUMWALT R. E., BLACK W. C. and SOBONYA R. E. (1994): The epidemiology of interstitial lung diseases. Am. J. Respir. Crit. Care Med., 150, 967-972.
14. DAWES K. E., CAMBREY A. D., CAMPA J. S., BISHOP J. E., MCANULTY R. J., PEACOCK A. J. and LAURENT G. J. (1996): Changes in collagen metabolism in response to endothelin-1: evidence for fibroblast heterogeneity. Int. J. Biochem. Cell. Biol., 28, 229-238.
15. EITZMAN D. T., MCCOY R. D., ZHENG X., FAY W. P., SHEN T., GINSBURG D. and SIMON R. H. (1996): Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J. Clin. Invest, 97, 232-237.
16. GIRI S. N., HYDE D. M., BRAUN R. K., GAARDE W., HARPER J. R. and PIERSCHBACHER M. D. (1997): Antifibrotic effect of decorin in a bleomycin hamster model of lung fibrosis. Biochem. Pharmacol., 54, 1205-1216.
17. GIRI S. N., HYDE D. M. and HOLLINGER M. A. (1993): Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax, 48, 959-966.
18. GURUJEYALAKSHMI G. and GIRI S. N. (1995): Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. Exp. Lung Res, 21, 791-808.
19. HAGIMOTO N., KUWANO K., KAWASAKI M., YOSHIMI M., KANEKO Y., KUNITAKE R., MAEYAMA T., TANAKA T. and HARA N. (1999): Induction of interleukin-8 secretion and apoptosis in bronchiolar epithelial cells by Fas ligation. Am. J. Respir. Cell Mol. Biol., 21, 436-445.
20. HAGIMOTO N., KUWANO K., MIYAZAKI H., KUNITAKE R., FUJITA M., KAWASAKI M., KANEKO Y. and HARA N. (1997): Induction of apoptosis and pulmonary fibrosis in mice in response to ligation of Fas antigen. Am. J. Respir. Cell Mol. Biol., 17, 272-278.
21. HAGIMOTO N., KUWANO K., NOMOTO Y., KUNITAKE R. and HARA N. (1997): Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. Am. J. Respir. Cell Mol. Biol., 16, 91-101.
22. HARRISON J. H. JR., HOYT D. G. and LAZO J. S. (1989): Acute pulmonary toxicity of bleomycin: DNA scission and matrix protein mRNA levels in bleomycin-sensitive and -resistant strains of mice. Mol. Pharmacol., 36, 231-238.
23. HELENE M., LAKE-BULLOCK V., ZHU J., HAO H., COHEN D. A. and KAPLAN A. M. (1999): T cell independence of bleomycin-induced pulmonary fibrosis. J. Leukoc. Biol., 65, 187-195.
24. HOGABOAM C. M., BONE-LARSON C. L., LIPINSKI S., LUKACS N. W., CHENSUE S. W., STRIETER R. M. and KUNKEL S. L. (1999): Differential monocyte chemoattractant protein-1 and chemokine receptor 2 expression by murine lung fibroblasts derived from Th1- and Th2-type pulmonary granuloma models. J. Immunol., 163, 2193-2201.
25. HOSENPUD J. D., BENNETT L. E., KECK B. M., EDWARDS E. B. and NOVICK R. J. (1998): Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet, 351, 24-27.
26. HSU S. C., GAVRILIN M. A., TSAI M. H., HAN J. and LAI M. Z. (1999): p38 mitogen-activated protein kinase is involved in Fas ligand expression. J. Biol. Chem., 274, 25769-25776.
27. HUBBARD R., JOHNSTON I. and BRITTON J. (1998): Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study. Chest, 113, 396-400.
28. HUBBARD R., JOHNSTON I., COULTAS D. B. and BRITTON J. (1996): Mortality rates from cryptogenic fibrosing alveolitis in seven countries. Thorax, 51, 711-716.
29. HUBBARD R., LEWIS S., RICHARDS K., JOHNSTON I. and BRITTON J. (1996): Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet, 347, 284-289.
30. HUBBARD R., VENN A., SMITH C., COOPER M., JOHNSTON I. and BRITTON J. (1998): Exposure to commonly prescribed drugs and the etiology of cryptogenic fibrosing alveolitis: a case-control study. Am. J. Respir. Crit. Care Med., 157, 743-747.
31. IWAI K., MORI T., YAMADA N., YAMAGUCHI M. and HOSODA Y. (1994): Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. Am. J. Respir. Crit. Care Med., 150, 670-675.
32. JOHNSTON I., BRITTON J., KINNEAR W. and LOGAN R. (1990): Rising mortality from cryptogenic fibrosing alveolitis. BMJ, 301, 1017-1021.
33. KATZENSTEIN A. L. and MYERS J. L. (1998): Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am. J. Respir. Crit. Care Med., 157, 1301-1315.
34. KEANE M. P., BELPERIO J. A., MOORE T. A., MOORE B. B., ARENBERG D. A., SMITH R. E., BURDICK M. D., KUNKEL S. L. and STRIETER R. M. (1999): Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. J. Immunol., 162, 5511-5518.
35. KORFHAGEN T. R., SWANTZ R. J., WERT S. E., MCCARTY J. M., KERLAKIAN C. B., GLASSER S. W. and WHITSETT J. A. (1994): Respiratory epithelial cell expression of human transforming growth factor-alpha induces lung fibrosis in transgenic mice. J. Clin. Invest., 93, 1691-1699.
36. KREMER S., BREUER R., LOSSOS I. S., BERKMAN N., CHRISTENSEN T. G., CONNOR M. W., GOLDSTEIN R. H. and OR R. (1999): Effect of immunomodulators on bleomycin-induced lung injury. Respiration, 66, 455-462.
37. KUMMER J. L., RAO P. K. and HEIDENREICH K. A. (1997): Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase. J. Biol. Chem., 272, 20490-20494.
38. KUWANO K., HAGIMOTO N., KAWASAKI M., YATOMI T., NAKAMURA N., NAGATA S., SUDA T., KUNITAKE R., MAEYAMA T., MIYAZAKI H. and HARA N. (1999): Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J. Clin. Invest., 104, 13-19.
39. KUWANO K., KUNITAKE R., KAWASAKI M., NOMOTO Y., HAGIMOTO N., NAKANISHI Y. and HARA N. (1996): P21Waf1/ /Cip1/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med., 154, 477-483.
40. KUWANO K., MIYAZAKI H., HAGIMOTO N., KAWASAKI M., FUJITA M., KUNITAKE R., KANEKO Y. and HARA N. (1999): The involvement of Fas-Fas ligand pathway in fibrosing lung diseases. Am. J. Respir. Cell Mol. Biol., 20, 53-60.
41. KUWANO K., NOMOTO Y., KUNITAKE R., HAGIMOTO N., MATSUBA T., NAKANISHI Y. and HARA N. (1997): Detection of adenovirus E1A DNA in pulmonary fibrosis using nested polymerase chain reaction. Eur. Respir. J., 10, 1445-1449.
42. LEE J. C., LAYDON J. T., MCDONNELL P. C., GALLAGHER T. F., KUMAR S., GREEN D., MCNULTY D., BLUMENTHAL M. J., HEYS J. R., LANDVATTER S. W., STRICKLER J. E., MCLAUGHLIN M. M., SIEMENS I. R., FISHER S. M., LIVI G. P., WHITE J. R., ADAMS J. L. and YOUNG P. R. (1994): A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature, 372, 739-746.
43. LIBBY D. M., GIBOFSKY A., FOTINO M., WATERS S. J. and SMITH J. P. (1983): Immunogenetic and clinical findings in idiopathic pulmonary fibrosis. Association with the B-cell alloantigen HLA-DR2. Am. Rev. Respir. Dis., 127, 618-622.
44. LIU A. N., MOHAMMED A. Z., RICE W. R., FIEDELDEY D. T., LIEBERMANN J. S., WHITSETT J. A., BRACIALE T. J. and ENELOW R. I. (1999): Perforin-independent CD8(+) T-cell-mediated cytotoxicity of alveolar epithelial cells is preferentially mediated by tumor necrosis factor-alpha: relative insensitivity to Fas ligand. Am. J. Respir. Cell Mol. Biol., 20, 849-858.
45. LOWIN B., HAHNE M., MATTMANN C. and TSCHOPP J. (1994): Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature, 370, 650-652.
46. LYMPANY P. A. and DU BOIS R. M. (1997): Diffuse lung disease: product of genetic susceptibility and environmental encounters. Thorax, 52, 92-94.
47. LYNCH J. P. 3rd and MCCUNE W. J. (1997): Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am. J. Respir. Crit. Care Med., 155, 395-420.
48. MADTES D. K., ELSTON A. L., HACKMAN R. C., DUNN A. R. and CLARK J. G. (1999): Transforming growth factor-alpha deficiency reduces pulmonary fibrosis in transgenic mice. Am. J. Respir. Cell Mol. Biol., 20, 924-934.
49. MAPEL D. W., HUNT W. C., UTTON R., BAUMGARTNER K. B., SAMET J. M. and COULTAS D. B. (1998): Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts. Thorax, 53, 469-476.
50. MIWA K., ASANO M., HORAI R., IWAKURA Y., NAGATA S. and SUDA T. (1998): Caspase 1-independent IL-1beta release and inflammation induced by the apoptosis inducer Fas ligand. Nat. Med., 4, 1287-1292.
51. MIYAZAKI Y., ARAKI K., VESIN C., GARCIA I., KAPANCI Y., WHITSETT J. A., PIGUET P. F. and VASSALLI P. (1995): Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. J. Clin. Invest., 96, 250-259.
52. MUTSAERS S. E., FOSTER M. L., CHAMBERS R. C., LAURENT G. J. and MCANULTY R. J. (1998): Increased endothelin-1 and its localization during the development of bleomycin-induced pulmonary fibrosis in rats. Am. J. Respir. Cell Mol. Biol., 18, 611-619.
53. MUTSAERS S. E., MARSHALL R. P., GOLDSACK N. R., LAURENT G. J. and MCANULTY R. J. (1998): Effect of endothelin receptor antagonists (BQ-485, Ro 47-0203) on collagen deposition during the development of bleomycin-induced pulmonary fibrosis in rats. Pulm. Pharmacol. Ther., 11, 221-225.
54. NAKAO A., AFRAKHTE M., MOREN A., NAKAYAMA T., CHRISTIAN J. L., HEUCHEL R., ITOH S., KAWABATA M., HELDIN N. E., HELDIN C. H. and TEN DIJKE P. (1997): Identification of Smad7, a TGF-beta-inducible antagonist of TGF-beta signalling. Nature, 389, 631-635.
55. NAKAO A., FUJII M., MATSUMURA R., KUMANO K., SAITO Y., MIYAZONO K. and IWAMOTO I. (1999): Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J. Clin. Invest., 104, 5-11.
56. OGASAWARA J., WATANABE-FUKUNAGA R., ADACHI M., MATSUZAWA A., KASUGAI T., KITAMURA Y., ITOH N., SUDA T. and NAGATA S. (1993): Lethal effect of the anti-Fas antibody in mice. Nature, 364, 806-809.
57. ORTIZ L. A., LASKY J., HAMILTON R. F. JR., HOLIAN A., HOYLE G. W., BANKS W., PESCHON J. J., BRODY A. R., LUNGARELLA G. and FRIEDMAN M. (1998): Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice. Exp. Lung Res., 24, 721-743.
58. POSTLETHWAITE A. E., HOLNESS M. A., KATAI H. and RAGHOW R. (1992): Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J. Clin. Invest., 90, 1479-1485.
59. RAGHU G., MASTA S., MEYERS D. and NARAYANAN A. S. (1989): Collagen synthesis by normal and fibrotic human lung fibroblasts and the effect of transforming growth factor-beta. Am. Rev. Respir. Dis., 140, 95-100.
60. RIEUX-LAUCAT F., BLACHERE S., DANIELAN S., DE VILLARTAY J. P., OLEASTRO M., SOLARY E., BADER-MEUNIER B., ARKWRIGHT P., PONDARE C., BERNAUDIN F., CHAPEL H., NIELSEN S., BERRAH M., FISCHER A. and LE DEIST F. (1999): Lympho-proliferative syndrome with autoimmunity: A possible genetic basis for dominant expression of the clinical manifestations. Blood, 94, 2575-2582.
61. SCOTT J., JOHNSTON I. and BRITTON J. (1990): What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. BMJ, 301, 1015-1017.
62. SIEGEL R. M. and FLEISHER T. A. (1999): The role of Fas and related death receptors in autoimmune and other disease states. J. Allergy Clin. Immunol., 103, 729-738.
63. SMITH R. E., STRIETER R. M., PHAN S. H., LUKACS N. W., HUFFNAGLE G. B., WILKE C. A., BURDICK M. D., LINCOLN P., EVANOFF H. and KUNKEL S. L. (1994): Production and function of murine macrophage inflammatory protein-1 alpha in bleomycin-induced lung injury. J. Immunol., 153, 4704-4712.
64. SMITH R. E., STRIETER R. M., PHAN S. H., LUKACS N. and KUNKEL S. L. (1998): TNF and IL-6 mediate MIP-1alpha expression in bleomycin-induced lung injury. J. Leukoc. Biol., 64, 528-536.
65. STEWART J. P., EGAN J. J., ROSS A. J., KELLY B. G., LOK S. S., HASLETON P. S. and WOODCOCK A. A. (1999): The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med., 159, 1336-1341.
66. STINSON J. C. and TOMKIN G. H. (1992): Familial cryptogenic fibrosing alveolitis: a case report. Irish J. Med. Sci., 161, 42-43.
67. UHAL B. D., GIDEA C., BARGOUT R., BIFERO A., IBARRA-SUNGA O., PAPP M., FLYNN K. and FILIPPATOS G. (1998): Captopril inhibits apoplosis in human lung epithelial cells: a potential antifibrotic mechanism. Am. J. Physiol., 275, L1013-1017.
68. VAN VALENBERG P. L., LAMMERS J. W., VAN DEN HOUT H. A., MOLEMA J. and VAN HERWAARDEN C. L. (1992): Chronic extrinsic allergic alveolitis in a family with idiopathic pulmonary fibrosis: the importance of histological diagnosis. Eur. Respir. J., 5, 1154-1157.
69. VARPELA E., TIILIKAINEN A., VARPELA M. and TUKIAINEN P. (1979): High prevalences of HLA-B15 and HLA-Dw6 in patients with cryptogenic fibrosing alveolitis. Tissue Antigens, 14, 68-71.
70. VERGNON J. M., VINCENT M., DE THE G., MORNEX J. F., WEYNANTS P. and BRUNE J. (1984): Cryptogenic fibrosing alveolitis and Epstein-Barr virus: an association? Lancet, 2, 768-771.
71. WALLACE W. A., RAMAGE E. A., LAMB D. and HOWIE S. E. (1995): A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA). Clin. Exp. Immunol., 101, 436-441.
72. WANG Q., WANG Y., HYDE D. M., GOTWALS P. J., KOTELIANSKY V. E., RYAN S. T. and GIRI S. N. (1999): Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters. Thorax, 54, 805-812.
73. WANGOO A., SHAW R. J., DISS T. C., FARRELL P. J., DU BOIS R. M. and NICHOLSON A. G. (1997): Cryptogenic fibrosing alveolitis: lack of association with Epstein-Barr virus infection. Thorax, 52, 888-891.
74. WARD W. F., MOLTENI A., TS'AO C. H. and HINZ J. M. (1990): Captopril reduces, collagen and mast cell accumulation in irradiated rat lung. Int. J. Radiat. Oncol. Biol. Phys., 19, 1405-1409.
75. ZHANG K., GHARAEE-KERMANI M., MCGARRY B., REMICK D. and PHAN S. H. (1997): TNF-alpha-mediated lung cytokine networking and eosinophil recruitment in pulmonary fibrosis. J. Immunol., 158, 954-959.
76. ZIEGENHAGEN M. W., ZABEL P., ZISSEL G., SCHLAAK M. and MULLER-QUERNHEIM J. (1998): Serum level of interleukin 8 is elevated in idiopathic pulmonary fibrosis and indicates disease activity. Am. J. Respir. Crit. Care Med., 157, 762-768.
77. ZIESCHE R., HOFBAUER E., WITTMANN K., PETKOV V. and BLOCK L. H. (1999): A preliminary study of long-term treatment with Interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med., 341, 1264-1269.